Ensysce Biosciences amends Series C preferred certificate to remove holder cash redemption provision

Ensysce Biosciences, Inc.

On September 25, 2026, Ensysce Biosciences amended the Series C Certificate of Designation to remove Section 6.5.3 and related references.
Section 6.5.3 had allowed holders to redeem Series C Preferred for cash after stockholder approval of conversion if Common Stock delivery failed, at then-current fair value.
The amendment was effective upon filing; a Certificate of Correction had been filed on August 6, 2026 after the original August 5, 2026 Series C designation.
Ensysce filed the amendment as Exhibit 3, and CEO Lynn Kirkpatrick signed the report on September 29, 2026.
The Series C Preferred Stock and Common Stock each have par value $0.0001 per share; Common Stock trades as ENSC on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.